Takeda Pharmaceutical Company Limited

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-30 am EDT			5-day change	1st Jan Change
4,153 ^JPY	+1.57%		+0.75%	+2.44%

09:41am	Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	RE
Apr. 26	EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	MT

Takeda Pharmaceutical Company Limited : Approval of a Once-Monthly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent in Japan

December 25, 2012 at 01:49 am EST

MarketScreener.com By The editorial team

December 25, 2012

Ajinomoto Pharmaceuticals Co., Ltd.
Eisai Co., Ltd.
Takeda Pharmaceutical Company Limited

Osaka and Tokyo Japan, December 25, 2012 --- Ajinomoto Pharmaceuticals Co., Ltd. (Tokyo, President: Tomoyasu Toyoda, "Ajinomoto Pharmaceuticals") and Takeda Pharmaceutical Company Limited (Osaka, President & CEO: Yasuchika Hasegawa, "Takeda") jointly announced today that "Actonel

Latest news about Takeda Pharmaceutical Company Limited

Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	03:41am	RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	Apr. 26	MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	Apr. 26	AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	Apr. 26	MT
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	Apr. 26	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy	Apr. 22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 19	MT
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	Apr. 19	MT
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	Apr. 18	CI
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	Apr. 18	DJ
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	Apr. 15	MT
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	Mar. 31	CI
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder	Mar. 26	MT
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	Mar. 26	CI
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	Mar. 20	MT
Takeda Pharmaceutical Receives FDA Approval to Expand Iclusig's Indication in Blood Cancer Sub-Type	Mar. 19	MT
Centogene, Takeda Pharmaceutical Collaborate on Lysosomal Storage Disorders Diagnostics	Mar. 19	MT
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® in Adult Patients with Newly Diagnosed Ph+ ALL	Mar. 19	CI
Takeda Pharmaceutical Says Mezagitamab Phase 2 Trial Shows 'Positive' Results in Primary Immune Thrombocytopenia Patients	Mar. 13	MT
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia	Mar. 13	CI
Toyota becomes Asia's most shorted large-cap stock - Hazeltree	Mar. 12	RE
India's Serum looks beyond COVID with new vaccines for malaria, dengue	Mar. 10	RE
EARNINGS: Hutchmed revenue surges, Craven House's loss widens	Feb. 28	AN

Chart Takeda Pharmaceutical Company Limited

Duration

Period

Chart Takeda Pharmaceutical Company Limited

More charts

Company Profile

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,089 JPY

Average target price

4,779 JPY

Spread / Average Target

+16.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+2.44%	40.94B
ELI LILLY AND COMPANY	+35.76%	664B
NOVO NORDISK A/S	+29.49%	567B
JOHNSON & JOHNSON	-7.20%	354B
MERCK & CO., INC.	+19.49%	330B
ABBVIE INC.	+4.34%	286B
ASTRAZENECA PLC	+13.49%	234B
NOVARTIS AG	+5.23%	199B
ROCHE HOLDING AG	-9.86%	196B
AMGEN INC.	-4.59%	148B

Other Pharmaceuticals